Clin2
NCT07073469Possibly a fitNot yet recruiting

Tenecteplase for strokes in the back of the brain: a later treatment window

Stroke Ischemic

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a clot-busting drug called tenecteplase for people who have a stroke in the back part of the brain and can be treated later than usual (up to 24 hours after symptoms start). The goal is to see if this drug can help improve recovery.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
330 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You had a stroke in the back part of your brain between 4.5 and 24 hours ago (or woke up with symptoms within that window)
  • Your stroke symptoms are at least moderately severe (score 4 or higher on a standard stroke scale)
  • Your brain scan shows limited damage (PC-ASPECTS score of 7 or more out of 10)
  • You were mostly independent before the stroke (able to do daily activities without help)
  • You are not at high risk for bleeding (no recent major surgery, bleeding problems, or certain blood thinners)
  • You are 18 years or older

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06010628Recruiting· Phase 4
Tenecteplase for stroke 4.5 to 6 hours after onset

This trial tests a medicine called tenecteplase (a clot-buster) for people who have a moderate or severe stroke caused by a clot and can be treated 4.5 to 6 hours after symptoms start. It aims to see if this medicine can help improve recovery.

Shenyang, None Selected
NCT07094763Recruiting
Tenecteplase for posterior stroke 4.5-24 hours after onset

This trial tests a clot-busting drug called tenecteplase for people who had a stroke affecting the back part of the brain (posterior circulation). It may be an option if you can get treatment between 4.5 and 24 hours after symptoms started.

Hefei
NCT06954155Recruiting· Phase 3
Tenecteplase for stroke treatment 24-72 hours after symptoms start

This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.

Beijing
NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou
NCT07361302Recruiting· Phase 3
Tenecteplase for stroke after 4.5 hours

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Buenos Aires
NCT07475949Not yet recruiting· Phase 3
Testing a clot-busting drug for wake-up strokes without advanced scans

This trial tests if the clot-busting drug tenecteplase can help people who have a stroke with an unknown start time (like waking up with symptoms) and cannot get an advanced brain scan. It aims to see if treatment within 3 hours of noticing symptoms is safe and effective.

Nanning, Guangxi

Hear when a new Stroke Ischemic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.